These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 31711058)

  • 1. High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms.
    Chan DL; Bernard EJ; Schembri G; Roach PJ; Johnson M; Pavlakis N; Clarke S; Bailey DL
    Neuroendocrinology; 2020; 110(11-12):950-958. PubMed ID: 31711058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide Therapy.
    De Silva MK; Chan DLH; Bernard EJ; Conner AJ; Mascall SL; Bailey DL; Roach PJ; Clarke SJ; Diakos CI; Pavlakis N; Schembri G
    Pancreas; 2024 Aug; 53(7):e560-e565. PubMed ID: 38986077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma.
    Satoh K; Patel D; Dieckmann W; Nilubol N; Kebebew E
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S714-20. PubMed ID: 26282908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volumetric parameters from [
    Langen Stokmo H; Aly M; Bowitz Lothe IM; Borja AJ; Mehdizadeh Seraj S; Ghorpade R; Miao X; Hjortland GO; Malinen E; Sorbye H; Werner TJ; Alavi A; Revheim ME
    J Neuroendocrinol; 2022 Jul; 34(7):e13170. PubMed ID: 35729738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [
    Sachpekidis C; Enqvist O; Ulén J; Kopp-Schneider A; Pan L; Mai EK; Hajiyianni M; Merz M; Raab MS; Jauch A; Goldschmidt H; Edenbrandt L; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2293-2307. PubMed ID: 38456971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.
    Chung HW; Lee KY; Kim HJ; Kim WS; So Y
    J Cancer Res Clin Oncol; 2014 Jan; 140(1):89-98. PubMed ID: 24194352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients.
    Zschaeck S; Li Y; Lin Q; Beck M; Amthauer H; Bauersachs L; Hajiyianni M; Rogasch J; Ehrhardt VH; Kalinauskaite G; Weingärtner J; Hartmann V; van den Hoff J; Budach V; Stromberger C; Hofheinz F
    PLoS One; 2020; 15(7):e0236841. PubMed ID: 32730364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Satoh K; Sadowski SM; Dieckmann W; Quezado M; Nilubol N; Kebebew E; Patel D
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):714-721. PubMed ID: 27638678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
    Vargas HA; Burger IA; Goldman DA; Miccò M; Sosa RE; Weber W; Chi DS; Hricak H; Sala E
    Eur Radiol; 2015 Nov; 25(11):3348-53. PubMed ID: 25916387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
    Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
    Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 17. Texture analysis of
    Nakajo M; Jinguji M; Nakabeppu Y; Nakajo M; Higashi R; Fukukura Y; Sasaki K; Uchikado Y; Natsugoe S; Yoshiura T
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):206-214. PubMed ID: 27613542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer.
    Miccò M; Vargas HA; Burger IA; Kollmeier MA; Goldman DA; Park KJ; Abu-Rustum NR; Hricak H; Sala E
    Eur J Radiol; 2014 Jul; 83(7):1169-1176. PubMed ID: 24767630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic tumour volume and total lesion glycolysis, measured using preoperative 18F-FDG PET/CT, predict the recurrence of endometrial cancer.
    Shim SH; Kim DY; Lee DY; Lee SW; Park JY; Lee JJ; Kim JH; Kim YM; Kim YT; Nam JH
    BJOG; 2014 Aug; 121(9):1097-106; discussion 1106. PubMed ID: 24397772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of preoperative metabolic tumour volume and total lesion glycolysis measured by (18)F-FDG PET/CT in squamous cell carcinoma of the oral cavity.
    Ryu IS; Kim JS; Roh JL; Cho KJ; Choi SH; Nam SY; Kim SY
    Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):452-61. PubMed ID: 24081448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.